Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy
Clinical trial NCT04620837 · UNKNOWN
Trial details
- NCT number
- NCT04620837
- Sponsor
- Chinese Academy of Medical Sciences
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-11-01
- Primary completion
- 2022-12-31
- Enrollment
- 25
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.